Beyond the big household names, smaller local manufacturers have told the government they can help make a new generation of mRNA medicines here.
A record share of executives missed out on bonuses last year but the highest paid CEO was Paul Perreault, the chief of biotech giant CSL, who took home $43 million.
The biotech giant says no doses of the AstraZeneca vaccine will go to waste as it doubles down on investment to protect Australia from other pandemics.
The global biotech giant has made its strongest comments since the start of the pandemic about the role it could play in onshore mRNA production.
Pfizer and CSL have both dampened hopes mRNA vaccines, including blockbuster COVID shots, could soon be made in Australia.
CSL will face little financial fallout from the government’s revised COVID rollout strategy, but the situation has confirmed the manufacturer can’t do it all.
The company manufacturing the AstraZeneca vaccine in Australia has shown little interest in changing its plans to produce 50 million doses.
The first 832,200 doses left CSL-Seqirus’ Parkville on the back of trucks on Wednesday morning, and another 2.5 million doses remain in cold storage as they undergo final testing and […]
PM Scott Morrison said without CSL’s local production, Australia would not be able to vaccinate the country. Within 12 weeks, GPs will be getting up to 1 million vaccine doses […]
Australia’s COVID-19 vaccine maker CSL says it is open to making booster shots for AstraZeneca for new variants of coronavirus but warns new formulas may not be available until the […]
CSL boss Paul Perrrault says the company is investigating how it can get involved in mRNA vaccine making in future but has flagged that development takes significant investment.
The biotechnology giant will spend more on R&D over the next six months as its research pipeline gets back up and running.
Futures are pointing to a drop of 34 points, or 0.5 per cent, at the open as major corporates are set to reveal their half-year earnings.
The global rollout of COVID-19 vaccines has failed to ignite CSL shares despite boosting offshore pharmaceutical firms.
The $132 billion biotechnology giant will redeploy hundreds of its staff to work on the Astra Zeneca/Oxford University COVID-19 vaccine candidate.
Investors and analysts remain unconvinced that biotechs will see big growth off the latest COVID-19 vaccine news.
The Australian biotech giant will launch a US study testing whether a treatment candidate helps treat COVID-19 related pneumonia.
Australian Ethical is asking the biotech giant to clarify how it will manage the risks posed by people in the US making donations more frequently to supplement their income.